<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58605">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781234</url>
  </required_header>
  <id_info>
    <org_study_id>UNM-246</org_study_id>
    <nct_id>NCT01781234</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajna Hamidovic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety and efficacy of intranasal insulin in abstinent smokers.
      Groups' (placebo vs. insulin) cognitive function and stress response will be compared.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>episodic  memory, salivary cortisol</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>working memory, continuous attention, psychomotor speed.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>subjective measure of mood and craving</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Tobacco Abstinence Syndrome</condition>
  <arm_group>
    <arm_group_label>Intranasal Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Insulin</intervention_name>
    <arm_group_label>Intranasal Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  smokers (&gt;10 cig/day) for the past 1 year

          -  normosmic olfactory function

        Exclusion Criteria:

          -  previous/current use of insulin

          -  current Diagnostic and Statistical Manual-IV-Revised (DSM-IV-R) Axis I disorder

          -  current pregnancy (or lactation)

          -  lifetime history of endocrine disease

          -  excessive alcohol use (&gt;25 standard units of alcohol/week)

          -  current use of illicit drugs

          -  current use of a smoking cessation aid (NRT, Chantix or Wellbutrin), or a
             psychotropic agent

          -  local infections, inflammation, structural abnormalities, or other nasal pathology

          -  current use of any medications administered intranasally, including intranasal
             steroids
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UNM College of Pharmacy</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajna Hamidovic, PharmD</last_name>
      <phone>505-272-4742</phone>
      <email>ahamidovic@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Ajna Hamidovic, PharmD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 20, 2013</lastchanged_date>
  <firstreceived_date>January 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Ajna Hamidovic</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
